s against the C. pneumoniae bacteria and for its once-weekly dosing.
ACES enrolled men and women at 28 centers across the country between 1999 and 2000. Pfizer, Inc., co-sponsored the study and supplied study medications.
"Although antibiotic treatment of patients with clinical coronary heart disease is not helpful, the ACES study was not designed to find the role of C. pneumoniae in the cause or progression of coronary heart disease. Different studies will be needed to determine the role of C. pneumoniae in the early, asymptomatic development of coronary heart disease," said J. Thomas Grayston, M.D, Professor of Epidemiology, University of Washington, Seattle, the study's principal investigator.
The ACES results are confirmed and extended by the similarly negative findings of the PROVE-IT trial published in the same issue of the New England Journal of Medicine. PROVE-IT tested a different antibiotic, a fluoroquinolone, and used a different treatment schedule with participants who were somewhat younger than those in ACES and who had an acute cardiac event at time of their enrollment in the study.
Page: 1 2 Related medicine news :1
Contact: NHLBI Communications Office
NIH/National Heart, Lung, and Blood Institute
. Childhood obesity indicates greater risk of school absenteeism, Penn study reveals2
. Penn study finds pro-death proteins required to regulate healthy immune function3
. New study shows promise in reducing surgical risks associated with surgical bleeding4
. New study counts the economic cost of persistent pain in Australia5
. UCLA researchers awarded $9M contract for study identifiying antibiotic treatment for MRSA6
. Most seniors now have drug coverage, U-M study shows7
. To gain muscle and lose fat, drink milk: study8
. Wheres the beef? Not enough of it is on elders plates, muscle-metabolism study suggests9
. Even older women at high risk have little interest in being tested for HIV, study finds10
. Metabolic study in mice could lead to good cholesterol boosters11
. Michigan-CDC study supports value of social restrictions during influenza pandemics